Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 23, 2021 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
June 15, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2020 16:06 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
May 27, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
May 27, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Announces Reverse Stock Split
February 05, 2020 12:45 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for...
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...